AI Article Synopsis
- - Vadadustat is an oral medication tested for treating anemia in patients with dialysis-dependent chronic kidney disease (CDK) and was compared to darbepoetin alfa (DA) in a phase 3b clinical trial.
- - The trial showed that the once-daily dosing of vadadustat was effective and met the noninferiority criteria when compared to DA, meaning it was at least as good as DA for maintaining hemoglobin levels, while the 3-times-weekly dosing did not meet this threshold.
- - Overall, both forms of vadadustat had similar safety profiles to DA, but more patients in the DA group needed additional treatments for low hemoglobin levels during the study.
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.34067/KID.0000000567 | DOI Listing |
Publication Analysis
Top Keywords
safety efficacy
4
efficacy vadadustat
4
vadadustat daily
4
daily three
4
three times
4
times weekly
4
weekly patients
4
patients dialysis-dependent
4
dialysis-dependent ckd
4
ckd anemia
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!